Fig. 2: A summary of diabetic macular oedema disease monitoring assessments conducted during the study. | Eye

Fig. 2: A summary of diabetic macular oedema disease monitoring assessments conducted during the study.

From: Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes

Fig. 2

A Shows the percentage of patients undergoing each assessment in year 1 (M12) and year 2 (M24) for treatment-naive and non-naive patients; B Shows the mean number of assessments per patient (accumulated figures are presented) in year 1 (M12) and year 2 (M24) for treatment-naive and non-naive patients. BCVA Best-corrected visual acuity, SD-OCT Spectral domain optical coherence tomography; VA Non-refracted visual acuity; Photo fundus photography; FFA fluorescein angiography, Slit lamp = slit lamp biomicroscopy; Ophthalmoscopy includes both direct and indirect assessment.

Back to article page